

Pre-clinical Safety and Efficacy Validation of GB2Ab, an ‘Induced-fit’ GFRAL Receptor Antagonist, for Cancer Cachexia Treatment and Potentiating Immuno-Oncology Response

Thor therapeutics Inc.



ONCOLOGY Candidate

Product Type	Antibody
Indication	• Primary: Cancer-associated cachexia (CAC) • Secondary: Immuno-oncology (IO) enhancement • Expansion: Metabolic disorders, muscle-wasting syndromes, and inflammatory diseases
Target	• GFRAL (GDNF Family Receptor Alpha-Like)
MoA (Mechanism of Action)	• TT-AB001, a proprietary anti-GFRAL antibody, effectively blocks GDF15-induced activation of the receptor • Direct inhibition of pathologically activated GFRAL neurons in the hindbrain • Restoration of healthy food intake and prevention of lean body mass loss in oncological patients
Competitiveness	• First-in-class induced-fit “locking” mechanism (vs. ligand neutralization) • Direct receptor targeting (GFRAL) enabling complete pathway blockade • Demonstrated full phenotypic recovery (body weight, muscle, fat, strength) • Dual therapeutic value: cachexia reversal + IO potentiation (“cold-to-hot” TME conversion) • Long half-life (>100 h) enabling Q2W/Q4W dosing convenience • Platform expandability across antibodies, ASOs, and AOCs
Development Stage	Candidate
Route of Administration	Parenteral (subcutaneous and intravenous)

Any unauthorized distribution or reproduction of this material is strictly prohibited.